RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Effetti pleiotropici degli attivatori di PPAR-gamma nella patologia neoplastica, infiammatoria e sclerogena.
• 2 - CONTROLLO DEL CICLO CELLULARE DA LIGANDI DI RECETTORI NUCLEARI
• 3 - Ruolo dell'ATP extracellulare nella patogenesi delle neoplasie tiroidee e nella modulazione di vecchi e nuovi markers di malattia
• 4 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 5 - Apoptosi e terapia del cancro: caratterizzazione di nuovi meccanismi e nuove molecole modulatrici dell'apoptosi
• 6 - BERSAGLI MOLECOLARI PER NUOVE TERAPIE ANTINEOPLASTICHE ATTRAVERSO LO STUDIO DI PROTEINE-SEGNALE CELLULARI E VIRALI E DI INIBITORI SPECIFICI
• 7 - Estrogeni, recettori steroidei e carcinoma prostatico: modulazione dei meccanismi biomolecolari coinvolti nella progressione e metastatizzazione del tumore
• 8 - Progressione dei carcinomi della ghiandola mammaria e della prostata: nuovi meccanismi ormonali e approcci terapeutici.
• 9 - Studio del signalling intracellulare e dei microdomini di membrana nel controllo dei processi proliferativi ed antiproliferativi nei tumori ipofisari.
• 10 - Meccanismi molecolari di carcinogenesi: validazione di nuovi bersagli per la diagnosi e la terapia

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA CLINICA
  • MEDICINA INTERNA
  • GASTROENTEROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Toscana

Bibliografia

1) Tontonoz P, et al.. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 1994;22:5628–5634.
2)steLehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953–12956.
3) Sarraf P, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046–1052
4) Toyota, M. et al. Peroxisome proliferator-activated receptor ? reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 2002;70:1565–1575.
5) Koga H, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001;33:1087–97.
6) Chung SH et al, Peroxisome proliferators-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn Cancer Res, 2002; 93:1358-65.
7) Ohta K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001; 86:2170-2177.
8) Ferruzzi P et al, Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005; 90:1332-39.
9) Betz MJ et al, Peroxisome proliferator-activated receptor gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 2005; 90: 3886-96.
10) Melillo RM, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-1081
11) Yang WL, et al. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22:1379–1383.
12).Satoh, T. et al. Activation of peroxisome proliferatoractivated receptor-g stimulates the growth arrest and DNAdamage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2000;21: 2171–2180.
13).Chen, G. G. et al. Apoptosis induced by activation of proliferator activated receptor- g is associated with Bcl-2? and NF-kB in human colon cancer. Life Sci 2002;70:2631–2646.
14) Han S et al, Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma independent signal pathways. Mol Cancer Ther 2006; 5:430-7.
15) Farrow B et al, Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003; 301:50-3.
16) Betz MJ et al, Peroxisome proliferator-activated receptor gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J of Clinical Endocrinol Metab 2005; 90: 3886-96.
17) Erbay E et al, IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 2003; 163:931-6.
18) Houston KD et al, Inhibition of proliferation and estrogen receptor signalling by peroxisome proliferators-activated receptor gamma ligands in uterine leiomyoma. Cancer Res, 2003; 63:1221-7.
19) Bonofiglio D et al, Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signalling in breast cancer cells. Clin Cancer Res 2005; 11:6139-47
20) Ogawa D et al, Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res 2006; 98:50-9.
21) Sikand K et al, Receptor Ck-dependent signalling regulates hTERT gene transcription. BMC Cell Biol 2006, 7:2.
22) Antonelli A, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006;91:614-20.
23) Saez E. et al. Activators of the nuclear receptor PPAR? enhance colon polyp formation. Nature Med 1998;4:1058–1061.
24). Lefebvre AM et al. Activation of the peroxisome proliferator-activated receptor ? promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med 1998;4:1053–1057.
25) Palakurthi SS, et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferatror-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-6218.
26) Hi R, et al. Characterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor a. Importance of a-helical structure in the transactivating function, J Biol Chem 1999; 274: 35152–35158.
27) Adams M, et al. Transcriptional activation by peroxisome proliferator-activated receptor ? is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site, J Biol Chem 1997; 272: 5128–5132.
28) Hauser G, et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 24: 18527–18533..
29) Yamashita D et al. The transactivating function of peroxisome proliferatoractivated receptor is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 2004; 1017–1029.
30) Pascual G, et al A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-g. Nature 2005; 437:759-763.
31). Alarcon-Vargas D, et al. SUMO in cancer-wrestlers wanted. Cancer Biol Ther. 2002;1:237-42

Parole Chiave

RECETTORI NUCLEARI, PPARGAMMA, CANCRO SURRENALICO, CANCRO EPATICO, CANCRO TIROIDEO